Evidence map›Paper›PMID 38540428›Full record

ArticleGenes2024

Kalliopi Liadaki, Efterpi Zafiriou, Themistoklis Giannoulis, Sofia Alexouda, Kleoniki Chaidaki, Polyxeni Gidarokosta, Angeliki-Viktoria Roussaki-Schulze, Sotirios G Tsiogkas, Athina Daponte, Zissis Mamuris and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genes, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. A review of core immuno-inflammatory mechanisms and key regulatory targets in psoriasis.American journal of clinical and experimental immunology · 2026
    Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Kalliopi LiadakiDepartment of Biochemistry and Biotechnology, University of Thessaly, Viopolis, 41500 Larissa, Greece.
Efterpi ZafiriouDepartment of Dermatology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Viopolis, 41500 Larissa, Greece.
Themistoklis GiannoulisDepartment of Animal Science, University of Thessaly, Gaiopolis, 41334 Larissa, Greece.ORCID 0000-0002-1842-5432
Sofia AlexoudaDepartment of Biochemistry and Biotechnology, University of Thessaly, Viopolis, 41500 Larissa, Greece.
Kleoniki ChaidakiDepartment of Dermatology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Viopolis, 41500 Larissa, Greece.
Polyxeni GidarokostaDepartment of Dermatology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Viopolis, 41500 Larissa, Greece.
Angeliki-Viktoria Roussaki-SchulzeDepartment of Dermatology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Viopolis, 41500 Larissa, Greece.
Sotirios G TsiogkasDepartment of Rheumatology and Clinical Immunology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Viopolis, 41500 Larissa, Greece.ORCID 0000-0001-8900-7281
Athina DaponteDepartment of Rheumatology and Clinical Immunology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Viopolis, 41500 Larissa, Greece.ORCID 0000-0002-4733-2585
Zissis MamurisDepartment of Biochemistry and Biotechnology, University of Thessaly, Viopolis, 41500 Larissa, Greece.ORCID 0000-0002-6868-8927
Dimitrios P BogdanosDepartment of Rheumatology and Clinical Immunology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Viopolis, 41500 Larissa, Greece.ORCID 0000-0002-9697-7902
Nicholas K MoschonasSchool of Medicine, University of Patras, 26500 Patras, Greece.ORCID 0000-0002-2556-537X
Theologia SarafidouDepartment of Biochemistry and Biotechnology, University of Thessaly, Viopolis, 41500 Larissa, Greece.
University of Thessaly · GRUniversity of Patras · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Moderate-to-severe psoriasis (Ps) treatment includes systemic drugs and biological agents. Apremilast, a small molecule primarily metabolized by cytochrome CYP3A4, modulates the immune system by specifically inhibiting phosphodiesterase type 4 (PDE4) isoforms and is currently used for the treatment of Ps and psoriatic arthritis (PsA). Clinical trials and real-world data showed variable efficacy in response among Ps patients underlying the need for personalized therapy. This study implements a candidate-gene and a network-based approach to identify genetic markers associated with apremilast response in forty-nine Greek Ps patients. Our data revealed an association of sixty-four SNPs within or near

Indexed as

Arthritis, PsoriaticPsoriasisCytochrome P-450 CYP3AHumansThalidomideapremilastCytochrome P-450 CYP3AThalidomideapremilastassociation studyCYP3A4pathway analysisPDE4protein interactomepsoriasisSNP

Identifiers

PMID38540428
PMCPMC10970167
OpenAlexW4392896874

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.